Should I buy Biogen shares?

Biogen shares are in the limelight. The stock rallied earlier this week but have I missed my opportunity to invest in the biotech firm?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Biogen (NASDAQ: BIIB) shares are receiving a lot of attention. The stock rallied on Monday after the US Food and Drug Administration (FDA) gave approval for the company’s Alzheimer’s drug.

I’m not surprised that Biogen shares soared on this news. But should I buy now? No, but I’ll be monitoring the stock. There’s a lot of hype now surrounding this biotech firm. Firstly, I’m waiting for this euphoria to subside. Secondly, I’ve analysed the FDA’s statement, and the company still has a lot of work to do. Unfortunately, the approval isn’t straightforward.

The approval

Let me start by saying that it’s always a big deal for a biotech company when a regulator, like the FDA, gives an approval. And this certainly applies for Biogen. 

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Biogen has developed an Alzheimer’s drug called aducanumab, which is sold under the brand name Aduhelm. On Monday, the FDA gave this drug an accelerated approval. But what does this mean?

Well, the FDA has indicated that the drug could provide a clinical benefit to Alzheimer’s patients. But I think the key thing to note is that the FDA now requires Biogen to conduct new randomised and controlled clinical trials to verify this.

I reckon the hard work for the company has just started. If the additional trials fail to confirm clinical benefit, then the FDA may have to withdraw the approval of the drug. There’s no guarantee the drug will be successful. Now that Biogen shares have rallied and are trading close to all-time highs, the stock is likely to be sensitive to any negative news.

The opportunity

If the biotech firm can get this right, then the upside is huge. According to the FDA’s website, Alzheimer’s is a debilitating disease that affects 6.2m Americans. It’s a progressive brain disorder that slowly attacks the memory and thinking skills. Eventually, it can impair the ability to carry out simple tasks.

Now here’s where Aduhelm comes in. So far the drug is the first of its kind approved for this devastating illness. In fact, scientists have been trying for years to treat the disease. This approval is the first new treatment approved for Alzheimer’s since 2003. In my opinion, this is a crucial inflection point for the battle against the illness.

But as I mentioned, Biogen has to conduct further trials. This will come at an additional cost to the firm, which could place pressure on profitability.

Market consensus

Just as Biogen shares rallied, institutional investors have also become bullish on the stock. Several investment banks have increased their price targets.

For example, Barclays has hiked its price target for Biogen to $395 from $265, but still maintains an ‘equal weight’ rating on the stock. Citigroup has upgraded the shares from a ‘sell’ to a ‘neutral’ and lifted its target from $200 to $440.

My view

I think Biogen has made a huge amount of progress to develop a treatment to tackle Alzheimer’s. And for this I commend the biotech company.

But there’s still a lot of risk involved and no guarantee the drug will be successful in future trials. So for now, I’ll be watching the stock closely.

Our best passive income stock ideas

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has recommended Barclays and Biogen. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature black couple enjoying shopping together in UK high street
Investing Articles

Here’s how a 50-year-old could aim for £1,400-a-month passive income from an ISA

Investing in a Stocks and Shares ISA is one way to target long-term passive income, even for those hitting their…

Read more »

Investing Articles

After hitting a new 52-week low can the Diageo share price ever recover? See what the experts say

Harvey Jones has taken a beating on the Diageo share price, and there's no end to his misery in sight.…

Read more »

Investing Articles

Should I cash in my Rolls-Royce shares?

This investor in Rolls-Royce shares is wondering whether now might be the best time to sell up and move on…

Read more »

Investing Articles

With gold above $3,000, is it time to consider buying this FTSE miner?

Here’s one FTSE 100 stock that should -- in theory -- benefit from the current global uncertainty and a rising…

Read more »

Investing Articles

3 possible ways to generate a £1k monthly second income in the stock market

Our writer outlines a trio of approaches someone could take to try and build a four-figure monthly second income from…

Read more »

Investing Articles

Is the booming BAE Systems share price a deadly trap?

The BAE system share price has been a huge beneficiary of today's geopolitical uncertainty but investors considering the stock should…

Read more »

Investing Articles

Thank you stock market: a rare chance to consider buying Nvidia stock?

Market forces have brought Nvidia stock and many of its peers down as the Nasdaq and S&P 500 reach correction…

Read more »

A couple celebrating moving in to a new home
Investing Articles

Time for a Berkeley Group share price recovery as FY guidance is confirmed?

After slumping in 2024, investors will want to see better from the Berkeley Group Holdings share price. Here's what the…

Read more »